The François Jacob Institute of Biology brings together five departments and three services
The last two years in scientific news
Find here all the scientific news and highlights about the François Jacob Institute of Biology.
The UMR1184S Autoimmune Diseases Team (IDMIT CEA-Jacobl) has published an article in Arthritis & Rheumatology confirming a direct pathogenic role for salivary epithelial cells in primary Sjögren syndrome.
In an article published in Oncogene, researchers from LRTS and LRIG (IRCM/CEA-Jacob) have shown that an increase in the expression of cellular prion protein driven by the ATM/TAK1/JUNK signaling pathway contributes to solid tumor radioresistance.
In an unprecedented work published in Brain, researchers from LMN (MIRCen/CEA-Jacob) showed that these abnormal tau proteins migrate from neurons to astrocytes, another type of cell within the brain, and remain toxic in the astrocytes as well.
In a partnership with IDMIT (CEA-Jacob) and Institut Pasteur, the Epigenetic and Environment Laboratory (LEE; CNRGH/CEA-Jacob) carried out two studies to evaluate DNA methylation in non-human primate models of immunodeficiency virus infections.
Glioblastomas are highly aggressive brain tumors with a very poor prognosis. Even with aggressive treatment, recurrence is nearly systematic. Researchers from IRCM (CEA-Jacob) have decrypted molecular mechanisms that enable treatment resistance and escape for a subpopulation of cells.
Researchers from MIRCen (CEA-Jacob) have shown that exposure to alpha-synuclein aggregates may affect dopaminergic neuron survival in Parkinson's disease by reducing astrocyte support for them.
In an international collaboration, a team from MIRCen (CEA-Jacob) studied the properties of toxic alpha-synuclein aggregates in fixed brain samples from patients, depending on their tissue origin and the type of synucleinopathy developed.
A new international study, published in Cell, co-leaded by IDMIT (CEA-Jacob) and the Department of Medical Microbiology of the University of Amsterdam, presents the results of preclinical trials of a new protein vaccine candidate against Covid-19.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.